In 698 adults with MASH and F2–F4c fibrosis, weekly zalfermin 30 mg plus semaglutide 2·4 mg did not significantly improve fibrosis without MASH worsening at 52 weeks vs placebo (24% vs 16%; p=0·19); semaglutide alone was nominally better (30%).
RCTn = 698
Loomba et al. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial